ORIGINAL RESEARCH article
Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1499701
This article is part of the Research TopicChallenges and Strategies in the Management of ER/PgR Low-Expression Breast Cancer: Exploring Fundamentals, Clinical Insights, and Treatment ApproachesView all 4 articles
Efficacy and safety of Eribulin-based Chemotherapy in HER2 negative advanced breast cancer patients: A Real-World Study
Provisionally accepted
- 1Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- 2Department of Radiology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Breast cancer is recognized as one of the most common cancers worldwide, exhibiting a notably high incidence rate among women in China. Despite significant advancements in therapeutic approaches, the prognosis for patients diagnosed with advanced stages of the disease remains poor. Therefore, there is an urgent necessity to investigate the effectiveness and safety of treatments such as Eribulin, a non-taxane microtubule inhibitor that is recommended for use beyond second-line therapy.Methods: This retrospective multicenter study assessed 105 patients with HER2-negative advanced breast cancer who received Eribulin treatment from 2020 to 2023.Results: With a median follow-up of 13.3 months, the median progression-free survival (PFS) was 6.0 months. Patients on early-line Eribulin had a significantly longer PFS (6.7 vs. 4.9 months, P = 0.038) than those on later lines. Combination therapy tended towards longer PFS than monotherapy (6.4 vs. 4.9 months; P = 0.319), albeit non-significantly. Combinations with PD-1 inhibitors or chemotherapy had a higher PFS than those with anti-angiogenic agents (P = 0.022). Among ER-negative patients in the combination therapy subgroup, HER2-zero tumors had a significantly longer PFS than HER2-low tumors (9.5 vs. 4.1 months, P = 0.026). The most frequently observed adverse events were hematological toxicity, with the majority classified as manageable in severity.The findings emphasize the potential of Eribulin in the treatment of HER2-negative advanced breast cancer, highlighting the need for further large-scale, prospective studies to refine and enhance treatment strategies.
Keywords: eribulin, breast cancer, HER2-low, combination therapy, Progression-free survival
Received: 21 Sep 2024; Accepted: 16 May 2025.
Copyright: © 2025 Li, Dan, Hu, Xiong and Yanxia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhao Yanxia, Department of Radiology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.